The latest news, announcements and press releases from Sinovac Biotech.
BEIJING--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovac’s annual capacity of CoronaVac® has reached 2 billion doses. At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China. It is estimated that over 100 million doses of CoronaVac have been administered during the vaccination rollout in different countries. The safety and effectiveness of CoronaVac® has been proven gradually along with the rollout of the vaccination around the world.
Brazil’s health regulator said on Monday it had suspended clinical trials of an experimental Chinese COVID-19 vaccine after an “adverse incident” involving one of the volunteers, in a surprise to the trial organisers who said that while there had been a death it was not related to the vaccine.
The setback for CoronaVac, developed by Chinese pharmaceutical firm Sinovac Biotech, came on the same day US pharmaceutical giant Pfizer said its vaccine candidate had shown 90 percent effectiveness, raising hopes of an end to the pandemic.
This is the News section of the company profile page for Sinovac Biotech on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.